Dermatology | Page 9 of 22 | Links Medicus Content Curation & Alerts in Medicine

Expert Consensus: Topical treatment of recurrent vulvovaginal candidiasis.

29 Apr, 2022 | 10:46h | UTC

Topical Treatment of Recurrent Vulvovaginal Candidiasis: An Expert Consensus – Women’s Health Reports

Consensus for the treatment of tinea pedis.

26 Apr, 2022 | 08:02h | UTC

Consensus for the Treatment of Tinea Pedis: A Systematic Review of Randomised Controlled Trials – Journal of Fungi

Guidelines: Cutaneous lymphomas.

25 Apr, 2022 | 00:38h | UTC

S2k-Guidelines – Cutaneous lymphomas (ICD10 C82 – C86): Update 2021 – Journal of the German Society of Dermatology

RCT: Long-term efficacy and safety of up to 108 weeks of Ixekizumab in pediatric patients with moderate to severe plaque psoriasis.

18 Apr, 2022 | 09:49h | UTC

Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial – JAMA Dermatology

Original Study: Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS) – British Journal of Dermatology

Commentary on Twitter

In this RCT, by 108 weeks of use of ixekizumab for pediatric psoriasis, PASI 75/90/100 were achieved in 92%/79%/55%, respectively, of children, with clearance of nails in 68%, scalp in 76%, genital lesions in 88%, and palm/sole involvement in 90%. https://t.co/vk73Z3MKi4

— JAMA Dermatology (@JAMADerm) April 13, 2022

Review: Cutaneous manifestations of monoclonal gammopathy.

14 Apr, 2022 | 08:21h | UTC

Cutaneous manifestations of monoclonal gammopathy – Blood Cancer Journal

M-A: Assessment of frequency of rosacea subtypes in patients with rosacea.

13 Apr, 2022 | 09:54h | UTC

Assessment of Frequency of Rosacea Subtypes in Patients With Rosacea: A Systematic Review and Meta-analysis – JAMA Dermatology (link to abstract – $ for full-text)

Commentary: Study Evaluates Prevalence of 4 Major Rosacea Subtypes – HCPLive

Commentary on Twitter

In this systematic review and meta-analysis, erythematotelangiectatic and papulopustular rosacea are the most common subtypes of #rosacea based on global data. https://t.co/2lWCjrIIWP

— JAMA Dermatology (@JAMADerm) April 7, 2022

Global burden of cutaneous melanoma in 2020 and projections to 2040.

31 Mar, 2022 | 08:11h | UTC

Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040 – JAMA Dermatology (free for a limited period)

Editorial: Melanoma Epidemiology—Pivoting to Low- and Middle-Income Countries (free for a limited period)

Commentary: Global Burden of Melanoma Considerable, Set to Rise by 2040 – HealthDay

RCT: Adalimumab introduction vs. methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis.

29 Mar, 2022 | 08:20h | UTC

Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study – The Lancet Rheumatology (link to abstract – $ for full-text)

Commentary: Adalimumab Addition vs. Methotrexate Escalation in Psoriatic Arthritis – RheumNow

Commentary on Twitter

NEW RESEARCH—A randomised, open-label, phase 4 trial supports the addition of #adalimumab over escalating #methotrexate in patients with #PsoriaticArthritis not reaching minimal disease activity after an initial methotrexate course https://t.co/LUpzAw71lD #LancetRheumatology pic.twitter.com/ouqTyITlxC

— The Lancet Rheumatology (@TheLancetRheum) February 28, 2022

RCT: Two phase 3 trials of Baricitinib for Alopecia Areata.

28 Mar, 2022 | 08:49h | UTC

Two Phase 3 Trials of Baricitinib for Alopecia Areata – New England Journal of Medicine

Commentary on Twitter

Alopecia areata is a distressing disorder of hair loss that is mediated partly by cytokines dependent on Janus kinases. The JAK1 and JAK2 inhibitor baricitinib reduced the extent of hair loss in two randomized trials over a period of 36 weeks. #AAD2022 https://t.co/oKKzGF7Q5S pic.twitter.com/gsgWJ1asZN

— NEJM (@NEJM) March 26, 2022

RCT: Hydrosurgical vs. conventional debridement of burns.

28 Mar, 2022 | 08:34h | UTC

Hydrosurgical and conventional debridement of burns: randomized clinical trial – British Journal of Surgery

Commentary on Twitter

In the April issue of BJS: Hydrosurgical and conventional debridement of burns: randomized clinical trial https://t.co/XoN6w3xkRU @AmyLightnerMD @bplwijn @des_winter @ksoreide @MalinASund @evanscolorectal @nfmkok @robhinchliffe1 @young_bjs pic.twitter.com/YSkczkqnTU

— BJS (@BJSurgery) March 25, 2022

Review | Imaging findings of malignant skin tumors: radiological–pathological correlation.

25 Mar, 2022 | 08:40h | UTC

Imaging findings of malignant skin tumors: radiological–pathological correlation – Insights into Imaging

Estimating overdiagnosis of melanoma using trends among black and white patients in the US.

24 Mar, 2022 | 08:52h | UTC

Estimating Overdiagnosis of Melanoma Using Trends Among Black and White Patients in the US – JAMA Dermatology (link to abstract – $ for full-text)

Commentary: Deadly form of skin cancer ‘overdiagnosed’ in some patients, study finds – UPI

Commentary from the author on Twitter (thread – click for more)

The wildest thing about this paper is we wrote it in 2017, then shelved it because of the initial push back in peer review. This experience taught me A LOT about when colleagues are ready to accept ideas that challenge their thinking. ?
1/9 https://t.co/hXDURXkwju

— Ade Adamson, MD MPP (@AdeAdamson) March 20, 2022

European guidelines on diagnosis and management of mucous membrane pemphigoid.

23 Mar, 2022 | 10:07h | UTC

Part I: European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part I – Journal of the European Academy of Dermatology and Venereology

Part II: European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part II – Journal of the European Academy of Dermatology and Venereology

RCT: Inhibition of Prekallikrein for hereditary angioedema.

23 Mar, 2022 | 10:02h | UTC

Inhibition of Prekallikrein for Hereditary Angioedema – New England Journal of Medicine (link to abstract – $ for full-text)

Phase 2 RCT: Prophylactic use of garadacimab in patients with hereditary angioedema.

Evaluation and Management of Angioedema in the Emergency Department

Vitamin B3, niacinamide and reducing skin cancer risk: what does the research say?

22 Mar, 2022 | 08:03h | UTC

Vitamin B3, niacinamide and reducing skin cancer risk: what does the research say? – The Conversation

Systematic Review: Strategies for using topical corticosteroids in children and adults with eczema.

21 Mar, 2022 | 08:33h | UTC

Strategies for using topical corticosteroids in children and adults with eczema – Cochrane Library

Summary: What is the best way to use topical corticosteroids to treat people with eczema? – Cochrane Library

Commentary on Twitter

What is the best way to use topical #corticosteroids to treat people with #eczema?
"Generally, stronger topical corticosteroids are probably more effective than weaker preparations". https://t.co/iaH6fzyXL4

Read the latest evidence from @CochraneSkin @CebdNottm pic.twitter.com/f01BO2FyDs

— Cochrane UK (@CochraneUK) March 17, 2022

Phase 2 RCT: Prophylactic use of garadacimab in patients with hereditary angioedema.

18 Mar, 2022 | 08:09h | UTC

Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial – The Lancet (link to abstract – $ for full-text)

Commentary: Garadacimab significantly reduces frequency of hereditary angioedema exacerbations – Physician’s Weekly

RCT: Oral contezolid vs. linezolid in adults with complicated skin and soft tissue infections.

18 Mar, 2022 | 07:54h | UTC

A Phase III multicentre, randomized, double-blind trial to evaluate the efficacy and safety of oral contezolid versus linezolid in adults with complicated skin and soft tissue infections – Journal of Antimicrobial Therapy (link to abstract – $ for full-text)

Commentary on Twitter

Phase III efficacy & safety of oral contezolid Vs linezolid in adults with c.SSTIs
?Non inferior
?Interestingly:Contezolid demonstrated significant lower incidence thrombocytopenia (0% Wow vs 2.3%) & leucopenia (0.3% vs 3.4%) than linezolid
?QIDP https://t.co/wSvxUInnkZ

— Antibiotic Steward Bassam Ghanem (@ABsteward) March 11, 2022

Follow-up data from 2 randomized trials: efficacy and safety of Upadacitinib in patients with moderate to severe atopic dermatitis.

18 Mar, 2022 | 07:48h | UTC

Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials – JAMA Dermatology

Systematic Review: Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome.

14 Mar, 2022 | 01:20h | UTC

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome – Cochrane Library

Summary: Which treatments that affect the whole body work best to treat severe skin reactions (Stevens-Johnson syndrome and toxic epidermal necrolysis)? – Cochrane Library

Review: Mycobacterial skin infection.

14 Mar, 2022 | 00:59h | UTC

Mycobacterial skin infection – Current Opinion in Infectious Diseases

RCT: Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis.

10 Mar, 2022 | 10:27h | UTC

Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis (COMPLETE-PsA): a double-blind, placebo-controlled, randomised, trial – The Lancet Rheumatology (link to abstract – $ for full-text)

Commentary: COMPLETE-PsA: Adding leflunomide to methotrexate may improve outcomes – medwireNews

Commentary on Twitter

NEW RESEARCH—A double-blind, placebo-controlled, randomised, trial comparing #methotrexate monotherapy with methotrexate plus #leflunomide combination therapy in psoriatic arthritis (COMPLETE-PsA) https://t.co/Fln7RlNl36 #LancetRheumatology pic.twitter.com/EqWSeHZQA2

— The Lancet Rheumatology (@TheLancetRheum) March 3, 2022